IFN-λ: A new spotlight in innate immunity against influenza virus infection

References

[1] Abboud G, Tahiliani V, Desai P, Varkoly K, Driver J, Hutchinson TE, Salek-Ardakani S (2015) Natural killer cells and innate interferon gamma participate in the host defense against respiratory vaccinia virus infection. J Virol 90:129–141

[2] Barr IG (2017) Assessing the potential pandemic risk of recent avian influenza viruses. Eur Respir J 49:1602517

[3] Bauer TT, Ewig S, Rodloff AC, Muller EE (2006) Acute respiratory distress syndrome and pneumonia: a comprehensive review of clinical data. Clin Infect Dis 43:748–756

[4] Bibert S, Roger T, Calandra T, Bochud M, Cerny A, Semmo N, Duong FHT, Gerlach T, Malinverni R, Moradpour D (2013) IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J Exp Med 210:1109–1116

[5] Brandes M, Klauschen F, Kuchen S, Germain RN (2013) A systems analysis identifies a feedforward inflammatory circuit leading to lethal influenza infection. Cell 154:197–212

[6] Broggi A, Tan Y, Granucci F, Zanoni I (2017) IFN-lambda suppresses intestinal inflammation by non-translational regulation of neutrophil function. Nat Immunol 18:1084–1093

[7] Bui CM, Chughtai AA, Adam DC, MacIntyre CR (2017) An overview of the epidemiology and emergence of influenza A infection in humans over time. Arch Public Health 75:15

[8] Chai N, Swem LR, Park S, Nakamura G, Chiang N, Estevez A, Fong R, Kamen L, Kho E, Reichelt M (2017) A broadly protective therapeutic antibody against influenza B virus with two mechanisms of action. Nat Commun 8:14234

[9] Chow KT, Gale M Jr (2015) SnapShot: interferon signaling. Cell 163 (1808–1808):e1801

[10] Ciancanelli MJ, Huang SX, Luthra P, Garner H, Itan Y, Volpi S, Lafaille FG, Trouillet C, Schmolke M, Albrecht RA (2015) Infectious disease. Life-threatening influenza and impaired interferon amplification in human IRF7 deficiency. Science 348:448–453

[11] Ciancanelli MJ, Abel L, Zhang SY, Casanova JL (2016) Host genetics of severe influenza: from mouse Mx1 to human IRF7. Curr Opin Immunol 38:109–120

[12] Dienz O, Rud JG, Eaton SM, Lanthier PA, Burg E, Drew A, Bunn J, Suratt BT, Haynes L, Rincon M (2012) Essential role of IL-6 in protection against H1N1 influenza virus by promoting neutrophil survival in the lung. Mucosal Immunol 5:258–266

[13] Fineberg HV (2014) Pandemic preparedness and response—lessons from the H1N1 influenza of 2009. N Engl J Med 370:1335–1342

[14] Galani IE, Triantafyllia V, Eleminiadou EE, Koltsida O, Stavropoulos A, Manioudaki M, Thanos D, Doyle SE, Kotenko SV, Thanopoulou K (2017) Interferon-lambda mediates non-redundant front-line antiviral protection against influenza virus infection without compromising host fitness. Immunity 46(875–890):e876

[15] Galmozzi E, Vigano M, Lampertico P (2014) Systematic review with meta-analysis: do interferon lambda 3 polymorphisms predict the outcome of interferon-therapy in hepatitis B infection? Aliment Pharmacol Ther 39:569–578

[16] Ginsberg J, Mohebbi MH, Patel RS, Brammer L, Smolinski MS, Brilliant L (2009) Detecting influenza epidemics using search engine query data. Nature 457:U1012–U1014

[17] Ivashkiv LB, Donlin LT (2014) Regulation of type I interferon responses. Nat Rev Immunol 14:36–49

[18] Iwasaki A, Pillai PS (2014) Innate immunity to influenza virus infection. Nat Rev Immunol 14:315–328

[19] Jiang JW, Li J, Fan WH, Zheng WN, Yu M, Chen C, Sun L, Bi YH, Ding C, Gao GF (2016) Robust Lys63-linked ubiquitination of RIG-I promotes cytokine eruption in early influenza B virus infection. J Virol 90:6263–6275

[20] Lazear HM, Nice TJ, Diamond MS (2015) Interferon-lambda: immune functions at barrier surfaces and beyond. Immunity 43:15–28

[21] Loo YM, Gale M Jr (2007) Influenza: fatal immunity and the 1918 virus. Nature 445:267–268

[22] Ma W, Huang H, Chen J, Xu K, Dai Q, Yu H, Deng F, Qi X, Wang S, Hong J (2017) Predictors for fatal human infections with avian H7N9 influenza, evidence from four epidemic waves in Jiangsu Province, Eastern China, 2013–2016. Influenza Other Respir Viruses 11:418–424

[23] Mendoza JL, Schneider WM, Hoffmann HH, Vercauteren K, Jude KM, Xiong A, Moraga I, Horton TM, Glenn JS, de Jong YP (2017) The IFN-lambda-IFN-lambdaR1-IL-10Rbeta complex reveals structural features underlying type III IFN functional plasticity. Immunity 46:379–392

[24] Nice TJ, Baldridge MT, McCune BT, Norman JM, Lazear HM, Artyomov M, Diamond MS, Virgin HW (2015) Interferon-lambda cures persistent murine norovirus infection in the absence of adaptive immunity. Science 347:269–273

[25] Peiris JS, Cheung CY, Leung CY, Nicholls JM (2009) Innate immune responses to influenza A H5N1: friend or foe? Trends Immunol 30:574–584

[26] Phillips S, Mistry S, Riva A, Cooksley H, Hadzhiolova-Lebeau T, Plavova S, Katzarov K, Simonova M, Zeuzem S, Woffendin C (2017) Peg-interferon lambda treatment induces robust innate and adaptive immunity in chronic hepatitis B patients. Front Immunol 8:621

[27] Poovorawan Y, Pyungporn S, Prachayangprecha S, Makkoch J (2013) Global alert to avian influenza virus infection: from H5N1 to H7N9. Pathog Glob Health 107:217–223

[28] Ramsey C, Kumar A (2011) H1N1: viral pneumonia as a cause of acute respiratory distress syndrome. Curr Opin Crit Care 17:64–71

[29] Schneider WM, Chevillotte MD, Rice CM (2014) Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol 32:513–545

[30] Short KR, Kroeze E, Fouchier RAM, Kuiken T (2014) Pathogenesis of influenza-induced acute respiratory distress syndrome. Lancet Infect Dis 14:57–69

[31] Tate MD, Deng YM, Jones JE, Anderson GP, Brooks AG, Reading PC (2009) Neutrophils ameliorate lung injury and the development of severe disease during influenza infection. J Immunol 183:7441–7450

[32] Teijaro JR (2015) The role of cytokine responses during influenza virus pathogenesis and potential therapeutic options. Curr Top Microbiol Immunol 386:3–22

[33] Zeuzem S, Arora S, Bacon B, Box T, Charlton M, Diago M, Dieterich D, Mur RE, Everson G, Fallon M (2011) Pegylated interferon-Lambda (PEGIFN-lambda) shows superior viral response with improved safety and tolerability versus PEGIFN alpha-2A in HCV patients (G1/2/3/4): emerge phase IIB through week 12. J Hepatol 54:S538–S539

RIGHTS & PERMISSIONS

2018 The Author(s) 2018